Clearmind Medicine Expands Intellectual Property Footprint As Hong Kong Releases Patents For PEA-Enhanced Psychedelic Drug Formulations

Clearmind Medicine Inc., a clinical-stage biotechnology company developing novel, non-hallucinogenic, second-generation neuroplastogen-based therapies for major under-treated health conditions, announced that the Intellectual Property Department in Hong Kong has published six of its patents. This marks another important step in strengthening the company’s growing global intellectual property portfolio. These patents focus on Clearmind’s proprietary combination therapies that integrate Palmitoylethanolamide (PEA) with a range of classic and emerging psychedelic compounds. PEA, which is sourced through the company’s partnership with NeuroThera Labs Inc. (TSXV: NTLX), is known for its anti-inflammatory and neuroprotective properties. By pairing PEA with well-researched psychedelics, Clearmind aims to create next-generation therapeutics with improved safety and effectiveness. The six published patents cover innovative formulations that combine PEA with MDMA, LSD, ketamine, ibogaine, psilocybin, and DMT. Each of these combinations is designed to work synergistically, potentially enhancing therapeutic outcomes while improving tolerability and supporting healthier neuroplasticity. These advances could offer new treatment possibilities for a wide range of mental health and neurological conditions, many of which have limited or inadequate therapeutic options today. According to Adi Zuloff-Shani, CEO of Clearmind Medicine, protecting these innovations is an important part of the company’s strategy. She noted that combining PEA with established psychedelic molecules allows Clearmind to build a strong and diverse pipeline of future drug candidates. This approach supports the company’s mission to address unmet medical needs and develop more effective solutions for mental health challenges.